Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, EZZ Life Science Holdings's Enterprise Value is A$9.23 Mil.
EZZ Life Science Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-2.71 Mil. Therefore, EZZ Life Science Holdings's EV-to-FCF for today is -3.40.
The historical rank and industry rank for EZZ Life Science Holdings's EV-to-FCF or its related term are showing as below:
ASX:EZZ'
s EV-to-FCF Range Over the Past 10 Years
Min: -4.01 Med: 8.35 Max: 45.14
Current: -4.01
During the past 6 years, the highest EV-to-FCF of EZZ Life Science Holdings was 45.14. The lowest was -4.01. And the median was 8.35.
ASX:EZZ's EV-to-FCF is ranked worse than 100% of 345
companies
in the Biotechnology industry
Industry Median: 14.39
vs ASX:EZZ: -4.01
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EZZ Life Science Holdings (ASX:EZZ) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EZZ Life Science Holdings's PE Ratio (TTM) for today is calculated as:
EZZ Life Science Holdings's share price for today is A$0.48.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. EZZ Life Science Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.061.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
EZZ Life Science Holdings EV-to-FCF Related Terms
EZZ Life Science Holdings EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, EZZ Life Science Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EZZ Life Science Holdings EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EZZ Life Science Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where EZZ Life Science Holdings's EV-to-FCF falls into.
EZZ Life Science Holdings's current Enterprise Value is A$9.23 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. EZZ Life Science Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-2.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EZZ Life Science Holdings (ASX:EZZ) has a EV-to-FCF of -3.40 as of Aug. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on EZZ Life Science Holdings and its competitors. According to the industry distribution chart, EZZ Life Science Holdings ranks #999999 out of 345 companies in the Biotechnology industry.
Is EZZ Life Science Holdings' EV-to-FCF too high?
EZZ Life Science Holdings' current EV-to-FCF is -3.40. Based on the distribution chart, EZZ Life Science Holdings ranks #999999 out of 345 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, EZZ Life Science Holdings has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does EZZ Life Science Holdings' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, EZZ Life Science Holdings ranks #999999 out of 345 companies for EV-to-FCF. This places EZZ Life Science Holdings in the lower half of its industry. The industry median EV-to-FCF is 14.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.39, based on 345 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on EZZ Life Science Holdings and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EZZ Life Science Holdings's current EV-to-FCF is -3.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EZZ Life Science Holdings stock overvalued right now?
Based on GuruFocus' analysis, EZZ Life Science Holdings (ASX:EZZ) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.45, compared to a current price of A$0.48 — trading 66.9% below its estimated fair value. The current EV-to-FCF is -3.40. EZZ Life Science Holdings' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For EZZ Life Science Holdings (ASX:EZZ), the current EV-to-FCF is -3.40 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EZZ Life Science Holdings (ASX:EZZ) Overvalued in 2026?
Based on GuruFocus' analysis, EZZ Life Science Holdings stock appears to be undervalued.
The current stock price of A$0.48 is trading 66.9% below its estimated GF Value™ of A$1.45.
GuruFocus considers EZZ Life Science Holdings to be Possible Value Trap.
Key valuation signals for ASX:EZZ:
EV-to-FCF: -3.40
GF Value™: A$1.45 vs. price of A$0.48 (66.9% below fair value)
No single metric tells the full story. See the ASX:EZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.
49GF Score
Get the complete analysis for ASX:EZZ
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EZZ has been successfully added to your 
